Nano-enabled Drug Delivery Technologies:
Players, products & prospects to 2015
| Price: £595.00 Approx $1,155.49 (USD) €888.70 (EUR) |
|
|---|---|
| Overview: | |
| Nanotechnology, the application of functional materials, devices, and systems of matter in the sub-100 nanometre scale has the potential to improve the delivery of approved and novel drugs through the design of nano-engineered drugs and the development of a plethora of nano-carriers. Whilst the pharmaceutical industry has been slow to invest resources into this innovative technology, a number of nanotechnology-focused companies have become established and are driving the future of this rapidly evolving market. Companies are adopting different strategies to improve the therapeutic potential, bioavailability, solubility and dosage of drugs through physical manipulation of therapeutic agents e.g. Nanocrystals, nanoparticles and nanosuspensions as well as the targeted delivery of small molecule and large molecular drugs using a range of nano-carriers e.g. carbon/ceramic nanostructures, dendrimers, liposomes, micelles and polymer nanoparticles. Twelve nano-enabled products are now approved for the treatment of a range of conditions from antibacterial infections to cancer and from the central nervous system to metabolic disorders. These products utilise a range of nanotechnologies including liposomes and polymeric micelles and have been developed by a handful of companies. Together these products generated global sales of over US$2.3 billion in 2006 and are forecast to reach sales of over US$3 billion by 2009. Competitive environment The report identifies 22 companies which are evaluating nano-enabled products in pre-clinical or clinical development. Of these, seven companies are likely to have products that will reach the market by 2015. A US$3.4 billion market in the making. By 2015, we forecast that nano-enabled products could generate sales in excess of US$3.4 billion driven by the uptake of innovative drug delivery systems including nanoparticle formulations, dendrimers and micelles and a new era of biocompatible nanoparticle coatings will begin to emerge that have applications in medical devices and dental implants. This is still very much an emerging market and we believe considerable commercial opportunities still exist for the pharma industry to form strategic alliances with nano-specialists and to tap into this powerful technology that may help to address the need for safer, more effective medicines. |
|
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr Cheryl Lee Barton / Publication Date: 16th November 2007
Contents:
Contents
Executive Summary 1
Competitor Ratio Analysis Summary 4
Introduction 6
Overview of nanotechnology: past, prese nt & future 7
Figure 1: Top ten applications of nanotechnology in developing countries 7
Nanotechnology: motivators & resistors 8
Motivators 8
Resistors 8
Nanotechnology: impact on product lifecycles 9
NANO TECHNOLOGY IN DRUG DELIVERY 10
Core nanotechnology used by the pharma industry 10
Nano-engineered drugs 10
Nano-carriers 10
Figure 2: Dendrimer structure 11
Figure 3: Liposome structure 12
Figure 4: Micelle structure 13
Current therapeutic application of nanotechnology in drug delivery 14
Leading brands that utilise nanotechnology delivery 14
Table 1: Nanotechnology-enabled approved drugs 14
Future commercial applications & opportunities 15
STRATEGIES OF DRUG DELIVERY COMPANIES 16
Leading nanotechnology drug delivery companies 16
Table 2: Leading nanotechnology-enabled drug delivery companies 16
Partnerships & acquisitions 18
Strategic development & commercialisation partnerships and joint ventures 18
Table 3: Recent partnerships & acquisitions in the nanotechnology field 19
Mergers & acquisitions 21
Table 4: Nanotechnology patents 21
THE NANOTECHNOLOGY MARKET 23
Now 2007 23
Table 5: Approved nano-enabled product sales 23
Future 2015 23
Table 6: Novel nano-enabled product sales 24
Table 7: Global nano-enabled product sales 24
COMPETITOR ANALYSIS 25
Movers & Shakers: Cutting edge or losing their grip 25
Table 8: Movers & shakers in nanotechnology drug delivery systems 26
COMPANY PROFILES 27
Abraxis Bioscience (www.abraxisbio.com 27
Table 9: Abraxis’ product pipeline 28
Table 10: Abraxis Drug Delivery Sales 28
Access Pharmaceuticals (www.accesspharma.com 29
Table 11: Access Pharmaceuticals product pipeline 30
AlphaRx Corporation (www.alpharx.com 31
Table 12: AlphaRx’ product pipeline 32
Table 13: AlphaRx’ pharmaceuticals drug delivery sales 32
AL ZA Corporation (www.alza.com 33
Table 14: ALZA’s drug delivery sales 33
Table 15: BioSante’s product pipeline 36
Table 16: BioSante’s drug delivery sales 37
Camurus AB (www.camurus.se 38
Table 17: Camurus AB’s product pipeline 39
Table 18: Camurus AB’s drug delivery sales 39
Eiffel Technologies (www.eiffeltechnologies.com 40
Table 19: Eiffel’s product pipeline 41
Elan Corporation (www.elan.com 42
Table 20: Elan’s product pipeline 43
Table 21: Elan’s drug delivery sales 43
Eurand (www.eurand.com 45
Table 22: Eurand’s product pipeline 46
Gilead Sciences (www.gilead.com 47
Table 23: Gilead Sciences’ product pipeline 47
Table 24: Gilead Sciences’ drug delivery sales 48
Nano Interface Technology (www.nanointerfacetech.com 49
Table 25: NITI’s product pipeline 49
Nano S Biotechnology GmbH (www.nano-s.com) 51
Table 26: Nano S’ product pipeline 51
NanoBio Corporation (www.nanobio.com 53
Table 27: NanoBio’s product pipeline 54
Table 28: NanoBio’s drug delivery sales 54
NanoBioMagnetics (www.nanobmi.com 55
Table 29: NanoBioMagnetics’ product pipeline 56
Nanobiotix (www.nanobiotix.com 57
Table 30: Nanobiotix’ product pipeline 57
NanoCarrier (www.nanocarrier.co.jp 59
Table 31: NanoCarrier’s product pipeline 60
Table 32: NanoCarrier’s drug delivery sales 60
Nanotechnology Victoria, Ltd (www.nanovic.com 61
Table 33: NanoVic’s product pipeline 61
NanoMaterials Technology (www.nanomt.com 63
Table 34: NanoMaterial’s product pipeline 64
Nanotherapeutics (www.nanotherapeutics.com 65
Table 35: Nanotherapeutics’ product pipeline 66
Table 36: Nanotherapeutics’ drug delivery sales 66
Novavax (www.novavax.com 68
Table 37: Novavax’s product pipeline 69
Table 38: Novavax’s drug delivery sales 70
SkyePharma (www.SkyePharma.com 71
Table 39: SkyePharma’s product pipeline 72
Table 40: SkyePharma’s product sales 72
Spherics (www.spherics.com 73
Table 41: Spheric’s product pipeline 74
APPENDIX 1 75
Table 42: Global nanotechnology approved drugs sales 2006A-20015E 75
APPENDIX 2 76
Table 43: Global nanotechnology developmental drugs sales 2006A-20015E 76
APPENDIX 3 77
Competitor Ratio Analysis Criteria 77
Table 44: Key nanotechnology delivery companies by 2015 78
BIBLIOGRAPHY 79
GLOSSARY 80
ACRONYMS 84
Table of Contents